openPR Logo
Press release

Sensorineural Hearing Loss Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos

07-10-2024 09:25 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Sensorineural Hearing Loss Pipeline and Clinical Trials

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sensorineural Hearing Loss pipeline constitutes 20+ key companies continuously working towards developing 21+ Sensorineural Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Sensorineural Hearing Loss Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sensorineural Hearing Loss Market.

The Sensorineural Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sensorineural Hearing Loss Pipeline Report: https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Sensorineural Hearing Loss treatment therapies with a considerable amount of success over the years.
• Sensorineural Hearing Loss companies working in the treatment market are Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Sensorineural Hearing Loss treatment
• Emerging Sensorineural Hearing Loss therapies in the different phases of clinical trials are- ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Sensorineural Hearing Loss market in the coming years.
• In January 2022, Sensorion reported that the Phase II AUDIBLE-S clinical trial investigating its drug candidate SENS-401 (Arazasetron) for the treatment of sudden sensorineural hearing loss (SSNHL) did not achieve its primary objective. The treatment did not demonstrate a significant improvement of 15 decibels (dB) in pure tone audiometry (PTA) within the affected ear compared to the placebo after four weeks of treatment, which was the primary endpoint.

Sensorineural Hearing Loss Overview
Sensorineural hearing loss (SNHL) occurs due to damage to inner ear structures or the auditory nerve. It accounts for over 90 percent of hearing impairment in adults. Typical causes of SNHL include prolonged exposure to loud noises, genetic predisposition, or the natural aging process.

Get a Free Sample PDF Report to know more about Sensorineural Hearing Loss Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Sensorineural Hearing Loss Drugs Under Different Phases of Clinical Development Include:
ACOU085: Acousia Therapeutics
• Cochlear Hair Cell Regeneration: Decibel Therapeutics
• HY01: Suzhou Pharmaceutical Technology Co.,Ltd
• AC102: AudioCure Pharma GmbH
• SENS-401: Sensorion

Sensorineural Hearing Loss Route of Administration
Sensorineural Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Sensorineural Hearing Loss Molecule Type
Sensorineural Hearing Loss Products have been categorized under various Molecule types, such as
• Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Sensorineural Hearing Loss Pipeline Therapeutics Assessment
• Sensorineural Hearing Loss Assessment by Product Type
• Sensorineural Hearing Loss By Stage and Product Type
• Sensorineural Hearing Loss Assessment by Route of Administration
• Sensorineural Hearing Loss By Stage and Route of Administration
• Sensorineural Hearing Loss Assessment by Molecule Type
• Sensorineural Hearing Loss by Stage and Molecule Type

DelveInsight's Sensorineural Hearing Loss Report covers around 21+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sensorineural Hearing Loss product details are provided in the report. Download the Sensorineural Hearing Loss pipeline report to learn more about the emerging Sensorineural Hearing Loss therapies
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Sensorineural Hearing Loss Therapeutics Market include:
Key companies developing therapies for Sensorineural Hearing Loss are - Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.

Sensorineural Hearing Loss Pipeline Analysis:
The Sensorineural Hearing Loss pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sensorineural Hearing Loss with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sensorineural Hearing Loss Treatment.
• Sensorineural Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sensorineural Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sensorineural Hearing Loss market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sensorineural Hearing Loss drugs and therapies
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sensorineural Hearing Loss Pipeline Market Drivers
• Rise in the Incidence of Sensorineural hearing loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Sensorineural Hearing Loss Market.

Sensorineural Hearing Loss Pipeline Market Barriers
• However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Sensorineural Hearing Loss Market growth.

Scope of Sensorineural Hearing Loss Pipeline Drug Insight
• Coverage: Global
• Key Sensorineural Hearing Loss Companies: Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others
• Key Sensorineural Hearing Loss Therapies: ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others
• Sensorineural Hearing Loss Therapeutic Assessment: Sensorineural Hearing Loss current marketed and Sensorineural Hearing Loss emerging therapies
• Sensorineural Hearing Loss Market Dynamics: Sensorineural Hearing Loss market drivers and Sensorineural Hearing Loss market barriers

Request for Sample PDF Report for Sensorineural Hearing Loss Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Sensorineural Hearing Loss Report Introduction
2. Sensorineural Hearing Loss Executive Summary
3. Sensorineural Hearing Loss Overview
4. Sensorineural Hearing Loss- Analytical Perspective In-depth Commercial Assessment
5. Sensorineural Hearing Loss Pipeline Therapeutics
6. Sensorineural Hearing Loss Late Stage Products (Phase II/III)
7. Sensorineural Hearing Loss Mid Stage Products (Phase II)
8. Sensorineural Hearing Loss Early Stage Products (Phase I)
9. Sensorineural Hearing Loss Preclinical Stage Products
10. Sensorineural Hearing Loss Therapeutics Assessment
11. Sensorineural Hearing Loss Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sensorineural Hearing Loss Key Companies
14. Sensorineural Hearing Loss Key Products
15. Sensorineural Hearing Loss Unmet Needs
16 . Sensorineural Hearing Loss Market Drivers and Barriers
17. Sensorineural Hearing Loss Future Perspectives and Conclusion
18. Sensorineural Hearing Loss Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports by DelveInsight

Car-t Market
www.delveinsight.com/report-store/car-t-market-forecast
DelveInsight's "CAR-T Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of CAR-T, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Varicose Vein Market
www.delveinsight.com/report-store/varicose-veins-market
DelveInsight's "Varicose Veins Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Varicose Veins, historical and forecasted epidemiology as well as the Varicose Veins market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vutrisiran Market
www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cryptococcosis Market
http://www.delveinsight.com/report-store/cryptococcosis-market
DelveInsight's "Cryptococcosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cryptococcosis, historical and forecasted epidemiology as well as the Cryptococcosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cancer Vaccines Market
http://www.delveinsight.com/report-store/cancer-vaccines-market
DelveInsight's "Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contrast-induced Nephropathy Market http://www.delveinsight.com/report-store/contrast-induced-nephropathy-market
DelveInsight's "Contrast-Induced Nephropathy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Contrast-Induced Nephropathy, historical and forecasted epidemiology as well as the Contrast-Induced Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Seborrheic Dermatitis Market http://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hypercoagulability Market
http://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Orthostatic Hypotension Market http://www.delveinsight.com/report-store/orthostatic-hypotension-market
DelveInsight's "Orthostatic Hypotension Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Orthostatic Hypotension, historical and forecasted epidemiology as well as the Orthostatic Hypotension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Point Of Care Glucose Testing Market http://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing - Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sensorineural Hearing Loss Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos here

News-ID: 3575262 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Sensorineural

Sudden sensorineural hearing loss Market is expected to reach USD 1.56 billion b …
Sudden sensorineural hearing loss (SSNHL) is an unexplained, rapid loss of hearing-typically in one ear-occurring over a 72-hour period or less. It often affects otherwise healthy individuals and is considered a medical emergency. While the exact cause remains unknown in many cases, viral infections, vascular compromise, and autoimmune disorders are among the suspected triggers. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70760 This condition affects approximately 5-27 per 100,000 people
Sensorineural Hearing Loss Pipeline: 20+ Innovators Shaping the Future of Hearin …
The sensorineural hearing loss space is entering a transformative phase with groundbreaking innovations in gene therapy and regenerative medicine. Pioneering companies such as Sensorion, AudioCure Pharma, Audion Therapeutics, Reyon Pharmaceutical, and Decibel Therapeutics are developing therapies aimed at repairing damaged sensory cells and restoring hearing function. These novel approaches are targeting the underlying causes of hearing loss at a molecular level, offering hope for patients with sensorineural hearing loss and
Acute Sensorineural Hearing Loss Treatment Market to Garner Brimming Revenues by …
Global Acute Sensorineural Hearing Loss Treatment Market: Introduction Acute sensorineural hearing loss occurs when the inner ear, the cochlea in the inner ear, or the nerve pathways between the ear and the brain get damaged. Audiometry tests can check human hearing more thoroughly and precisely. During these tests, an audiologist tests the patient's hearing ability by using earphones. A series of different sounds and volume levels is sent to each ear
Acute Sensorineural Hearing Loss Treatment Market: Which application is anticipa …
The report attempts to offer high-quality and accurate analysis of the global Acute Sensorineural Hearing Loss Treatment Market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Acute Sensorineural Hearing Loss Treatment market that are impacting their business. Readers can become aware of crucial opportunities available
EU grants orphan drug status to Strekin’s STR001 for Sudden Sensorineural Hear …
European Medicine Agency (EMA) has granted orohan drug designation to Sterkin AG, a clinical stage biopharmaceutical company’s development candidate STR001 for the treatment of patients with Sudden Sensorineural Hearing Loss. FDA and EMA grants orphan drug designation to those products like drugs and therapies that treat rare diseases. The administration defines rare diseases as those affecting fewer than 200,000 people in United States. Orphan drug designation provides certain financial benefits such
Therapeutics Clinical Trials On Acute Sensorineural Hearing Loss: Global Review, …
Researchmoz added Most up-to-date research on "Therapeutics Clinical Trials On Acute Sensorineural Hearing Loss: Global Review, H1, 2017" to its huge collection of research reports. GlobalData's clinical trial report, Acute Sensorineural Hearing Loss Global Clinical Trials Review, H1, 2017" provides an overview of Acute Sensorineural Hearing Loss clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Sensorineural Hearing Loss. Report includes an overview of